The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resect… (NCT07704645) | Clinical Trial Compass
Not Yet RecruitingPhase 2
The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer
China180 participantsStarted 2026-08
Plain-language summary
This study is an open-label, multicenter phase II clinical trial of adebelizumab combined with other anti-tumor therapies in patients with non-small cell lung cancer. The aim of this study was to evaluate the safety, tolerability and efficacy of adebelizumab combined with other anti-tumor therapies in patients with resectable non-small cell lung cancer ( NSCLC )
Who can participate
Age range
18 Years – 70 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. voluntarily participate in this clinical study, understand the research procedure and be able to sign the informed consent in writing ;
. At the time of signing the informed consent form, the age is 18-70 years old ( including both ends ), both men and women can.
.Combined genetic requirements : non-squamous cell carcinoma subjects must undergo EGFR gene detection and ALK gene and or immunohistochemical detection.
.Can provide tumor tissue specimens, which can be archived or freshly obtained specimens for biomarker detection.
.According to the RECIST v1.1 standard, subjects must have measurable target lesions examined by CT or MRI. Tumor imaging evaluation was performed within 28 days before the first administration.
.There is sufficient hematology and organ function, as defined by the results of laboratory tests, to be completed within 7 days prior to the first dose of treatment : 9.Women of childbearing age must have a serum pregnancy test within 7 days before the first administration, and the result is negative. Women of childbearing age and men whose partners are women of childbearing age must agree to use an efficient method of contraception from the date of signing the informed consent to at least 26 weeks ( female subjects ) or 14 weeks ( male subjects ) after the last administration.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial combines adalimumab — which is typically used for autoimmune conditions — with other anti-tumor therapies before surgery for resectable non-small cell lung cancer; can you explain why adding adalimumab might be beneficial in my situation, and what is currently known about how this combination works?
2Since this is a Phase 2 trial that hasn't started enrolling patients yet, what does that mean for how much safety and effectiveness data will be available by the time I might be able to participate, and should I consider standard neoadjuvant treatment options in the meantime?
3The trial measures pathological complete response — meaning no remaining tumor found at surgery — as its main goal; how does the pCR rate achieved with this combination compare to what I might expect from the standard treatment approaches already available to me?
4Because this study uses adalimumab, which affects the immune system, what additional risks or side effects should I be aware of compared to other pre-surgical treatment options for resectable lung cancer, and how might those risks affect my recovery and ability to have surgery?
5Given that this trial is not yet recruiting, how long might it be before it opens and I could realistically enroll, and is waiting for this trial the right call given the stage and urgency of my lung cancer?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Pathological complete response (pCR) rate: pCR is defined as the absence of any residual tumor at the time of surgical resection.
Timeframe: All results are expected to be obtained in the last participant three months after surgery.
. Small cell lung cancer ( SCLC ) and NSCLC mixed tumors confirmed by histology or cytology contain non-NSCLC pathological types such as small cell components.
.Have previously received systematic anti-tumor therapy for non-small cell lung cancer other than this study ( including clinical research drugs ) ; 4.Participants who had received or planned to receive local treatment such as chest radiotherapy or ablation ;